Rheumnow Podcast

Women with Rheumatic Disease (11.4.2022)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

Dr Nimesh Dayal on the Use of axSpA Endpoints in Clinical Practice Sponsored by AbbVie Medical Affairs

Dr. Nimesh Dayal (Orlando Health-Health Central Hospital, Orlando, FL) discusses the relevance of clinical endpoints and guidelines for ax-SpA in clinical practice.

Infections & Lupus (10.28.2022)

Dr. Jack Cush discussess the news and journal reports from the past week on RheumNow.com . This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.

ACR Award Winners (10.21.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

AOSD - Adult-onset Still’s disease

Review of Adult-onset Still's Disease by Dr. Jack Cush, Executive Editor of RheumNow.com

Primer on Clinical Trials (10.14.2022)

Dr. Jack Cush reviews:
- Should you do clinical trials?
- how to start in clinical trials
- Types of studies
- Benefits to research

Thats Not My Name (10.7.2022)

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in additon to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Perspectives on the safety of a JAK inhibitor in RA, PsA, and AS – Featuring Drs Wickersham, Winthrop, and Ritchlin Sponsored by AbbVie Medical Affairs

Drs. Pendleton Wickersham (Arthritis Associates PA, San Antonio, TX), Kevin Winthrop (OHSU, Portland, OR), and Christopher Ritchlin (URMC, Rochester, NY) come together to share their experiences discussing with patients the benefit-risk of a JAK inhibitor.

Great and Not-So Great (9.30.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.

Heavy Metal Rheumatology (9.23.2022)

Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me (jackcush@rheumnow.com) or recording your suggestion using the "Ask Cush Anything" link on our email and website.